Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2025 | $36.00 | Overweight → Equal Weight | Wells Fargo |
| 1/27/2025 | $30.00 → $40.00 | Equal-Weight → Overweight | Morgan Stanley |
| 1/24/2025 | Outperform → Perform | Oppenheimer | |
| 12/20/2024 | $36.00 → $40.00 | Outperform → Market Perform | BMO Capital Markets |
| 12/17/2024 | $35.00 → $39.00 | Buy → Neutral | BofA Securities |
| 10/16/2024 | $30.00 → $34.00 | Outperform | RBC Capital Mkts |
| 9/19/2024 | $30.00 | Neutral | UBS |
| 4/11/2024 | $25.00 | Overweight → Equal Weight | Barclays |
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
– Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% – – Additional results from dose-finding cohorts will also be presented – Exelixis, Inc. (NASDAQ:EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as well as data from multiple dose-escalation cohorts from STELLAR-002, will be presented at the 2025 American Society of Clinical Oncology
- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27. William Blair 45th Annual Growth Stock Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 10:00 a.m. CT / 8:00 a.m. PT on Tuesday, June 3 in Chicago. Jefferies Global Healthcare Conference 2025: Exelixis is scheduled to present at 7:35 a.m. ET / 4:35 a.m. PT on Wednesday, June 4 in New York City.
Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ:EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1). The molecule was discovered in part through a collaboration between Exelixis and Invenra. About Invenra Inc. Invenra Inc. pioneers the discove
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13G - EXELIXIS, INC. (0000939767) (Subject)
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
144 - EXELIXIS, INC. (0000939767) (Subject)
144 - EXELIXIS, INC. (0000939767) (Subject)
10-Q - EXELIXIS, INC. (0000939767) (Filer)
TORONTO, Oct. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI) (OTCQB:AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (NASDAQ:EXEL), as a director of the Company, effective October 15th, 2024. Mr. Haley will be replacing Sheetal Jaitly, who is stepping down as a director after a period of dedicated service and contributions to the Company. As NetraMark focuses on advancing its technology for late phas
– Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 – – Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance of $925 million - $975 million – – Appointment of two new board members, Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., with extensive drug development and corporate governance expertise – – Implementing corporate restructuring to focus R&D resources on clinical stage and IND-enabling activities to maximize pipeline success and operational efficiency – – Board of Directors authorized $450 million share repurchase in 2024 after successful completi
-- Dr. Peterson's extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran oncology drug development leader whose experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise. "With a
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
Wells Fargo downgraded Exelixis from Overweight to Equal Weight and set a new price target of $36.00
Morgan Stanley upgraded Exelixis from Equal-Weight to Overweight and set a new price target of $40.00 from $30.00 previously
Oppenheimer downgraded Exelixis from Outperform to Perform
- Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 - - Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX® d
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event
- Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion for the Fiscal Year 2024 - - Cabozantinib Franchise Achieved $1.81 billion in U.S. Net Product Revenues for the Fiscal Year 2024, including $515 million for the Fourth Quarter of 2024 - - GAAP Diluted EPS of $0.48 for the Fourth Quarter of 2024, $1.76 for the Fiscal Year 2024 - - Non-GAAP Diluted EPS of $0.55 for the Fourth Quarter of 2024, $2.00 for the Fiscal Year 2024 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectiv